Monoamine oxidase inhibitors were linked to the highest risk for cardiovascular Standardized MedDRA Queries. Dopamine reuptake inhibition and binding inhibition are linked to antidepressant-related ...
Stacker on MSN
New anxiety medications are in the pipeline for 2026
LifeStance Health reports new anxiety medications are expected for 2026, featuring innovative treatments in clinical trials ...
Narcolepsy can lead to excessive daytime sleepiness, as well as cataplexy, a sudden loss of muscle tone. Other symptoms can include sleep paralysis and hallucinations that occur both during sleep ...
Synendos Therapeutics AG has received approval from the European Medicines Agency (EMA) to initiate a first-in-human trial of its lead asset, SYT-510, a first-in-class inhibitor that modulates a newly ...
Plant City, Florida - January 09, 2026 - PRESSADVANTAGE - WhiteSands Alcohol & Drug Rehab Plant City has published ...
LOS ANGELES — The novel norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI) centanafadine (Otsuka Pharmaceutical Co., Ltd.) is effective and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback